WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010120592) COMBINATION THERAPY USING AN ANTI-EGFR AGENT(S) AND IGF-1R SPECIFIC INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/120592    International Application No.:    PCT/US2010/030022
Publication Date: 21.10.2010 International Filing Date: 06.04.2010
IPC:
A61K 39/395 (2006.01), A61K 31/517 (2006.01)
Applicants: MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue Rahway, New Jersey 07065-0907 (US) (For All Designated States Except US).
SATHYANARAYANAN, Sriram [IN/US]; (US) (For US Only).
KASIBHATLA, Shailaja [US/US]; (US) (For US Only).
WINTER, Christopher [US/US]; (US) (For US Only).
CHASTAIN, Michael [US/US]; (US) (For US Only)
Inventors: SATHYANARAYANAN, Sriram; (US).
KASIBHATLA, Shailaja; (US).
WINTER, Christopher; (US).
CHASTAIN, Michael; (US)
Common
Representative:
MERCK SHARP & DOHME CORP.; 126 East Lincoln Avenue Rahway, New Jersey 07065-0907 (US)
Priority Data:
61/169,768 16.04.2009 US
Title (EN) COMBINATION THERAPY USING AN ANTI-EGFR AGENT(S) AND IGF-1R SPECIFIC INHIBITORS
(FR) POLYTHÉRAPIE UTILISANT UN OU PLUSIEURS AGENTS ANTI-EGFR ET DES INHIBITEURS CIBLANT L'IGF-1R
Abstract: front page image
(EN)The combination of an IGF-1R antagonist such as a humanized antibody and an anti-proliferative drug is described. In a preferred embodiment, the present invention describes the combination of an IGF-1R antibody and an anti-proliferative drug belonging to the EGFR-inhibitor class, which is preferably erlotinib. The combination according to the present invention is useful for the treatment of tumours, including IGF-1R and /or EGFR mediated or dependent tumours.
(FR)La présente invention concerne l'association d'un antagoniste de l'IGF-1R, tel qu'un anticorps humanisé, et un médicament antiprolifératif. Selon un mode de réalisation préféré, la présente invention concerne la combinaison d'un anticorps anti-IGF-1R et d'un médicament antiprolifératif appartenant à la catégorie des inhibiteurs de l'EGFR, de préférence l'erlotinib. Selon la présente invention, la combinaison est utile pour le traitement de tumeurs, notamment les tumeurs IGF-1R-dépendantes et/ou EGFR-dépendantes ou les tumeurs à médiation de l'IGF-1R et/ou de l'EGFR.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)